Recommended submission dates for veterinary medicinal products
Submitted by Anonymous (not verified) on 17 September 2024 - 10:30
Recommended submission dates for veterinary medicinal products
Agenda - Information session on the pilot for expert panels' advice for orphan medical devices
Submitted by Anonymous (not verified) on 17 September 2024 - 8:29
Agenda - Information session on the pilot for expert panels' advice for orphan medical devices
Lidocaine (bovine): European Public MRL Assessment Report (EPMAR) - CVMP
Submitted by Anonymous (not verified) on 16 September 2024 - 15:53
Lidocaine (bovine): European Public MRL Assessment Report (EPMAR) - CVMP
Lidocaine (porcine species): European Public MRL Assessment Report (EPMAR) - CVMP
Submitted by Anonymous (not verified) on 16 September 2024 - 15:51
Lidocaine (porcine species): European Public MRL Assessment Report (EPMAR) - CVMP
Decision of the Executive Director on transparency measures for senior staff leaving the Agency
Submitted by Anonymous (not verified) on 16 September 2024 - 15:47
Decision of the Executive Director on transparency measures for senior staff leaving the Agency
Joint Committee Opinion 27/2020 on criteria and restrictions for senior staff applying for occupational activities within two years after leaving the Agency
Submitted by Anonymous (not verified) on 16 September 2024 - 15:45
Joint Committee Opinion 27/2020 on criteria and restrictions for senior staff applying for occupational activities within two years after leaving the Agency
Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation
Submitted by Anonymous (not verified) on 16 September 2024 - 15:35
Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation
Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application
Submitted by Anonymous (not verified) on 16 September 2024 - 15:33
Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application
Guidance for competent authorities on how to highlight VNRAs
Submitted by Anonymous (not verified) on 16 September 2024 - 15:30
Guidance for competent authorities on how to highlight VNRAs
Agenda of the CHMP meeting 16-19 September 2024
Submitted by Anonymous (not verified) on 16 September 2024 - 14:18
Agenda of the CHMP meeting 16-19 September 2024